Pfizer Inc. (PFE.MX)
- Previous Close
435.90 - Open
435.00 - Bid 435.00 x 600000
- Ask 438.00 x 600000
- Day's Range
434.00 - 438.00 - 52 Week Range
429.00 - 720.00 - Volume
3,038 - Avg. Volume
19,546 - Market Cap (intraday)
2.469T - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
68.99 - EPS (TTM)
6.32 - Earnings Date May 1, 2024
- Forward Dividend & Yield 28.53 (6.54%)
- Ex-Dividend Date May 9, 2024
- 1y Target Est
--
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
www.pfizer.com88,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: PFE.MX
Performance Overview: PFE.MX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PFE.MX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PFE.MX
Valuation Measures
Market Cap
2.45T
Enterprise Value
3.44T
Trailing P/E
68.89
Forward P/E
11.51
PEG Ratio (5yr expected)
0.25
Price/Sales (ttm)
2.46
Price/Book (mrq)
1.62
Enterprise Value/Revenue
58.81
Enterprise Value/EBITDA
359.99
Financial Highlights
Profitability and Income Statement
Profit Margin
3.62%
Return on Assets (ttm)
1.55%
Return on Equity (ttm)
2.35%
Revenue (ttm)
58.5B
Net Income Avi to Common (ttm)
2.13B
Diluted EPS (ttm)
6.32
Balance Sheet and Cash Flow
Total Cash (mrq)
12.69B
Total Debt/Equity (mrq)
84.37%
Levered Free Cash Flow (ttm)
1.02B
Company Insights: PFE.MX
PFE.MX does not have Company Insights